Ureteral Stent Size Measurement Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00919386|
Recruitment Status : Completed
First Posted : June 12, 2009
Last Update Posted : July 31, 2015
|Condition or disease||Phase|
|Quality of Life||Phase 4|
|Study Type :||Observational|
|Actual Enrollment :||17 participants|
|Official Title:||Three Methods of Ureteral Stent Measurement: Which Method Improves Quality of Life After Ureteral Stenting?|
|Study Start Date :||April 2009|
|Primary Completion Date :||May 2014|
|Study Completion Date :||May 2014|
1 Direct ureteric measurement
This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
2 Based on patient height
We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2" will receive a 22 cm stent, 5'3"-5'7" will get a 24 cm stent, 5'8"-5'10" will get a 26 cm stent, 5'11" to 6'1" will get a 28 cm stent, and all patients greater than 6'2" will receive a 30 cm stent.
3 Based on a predetermined formula
We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
- To determine the difference in patient quality of life (QOL), post-op symptoms, and pain medication and anticholinergic use in patients who receive ureteral stents where size is determined by direct measurement, patient height,a standardized formula. [ Time Frame: within 4 weeks post-porcedure ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00919386
|United States, West Virginia|
|Urology center of charleston|
|Charleston, West Virginia, United States, 25301|
|Principal Investigator:||Samuel Deem, M.D.||CAMC Medical Staff - with admitting privileges|